Early Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily, have been fully informed about the study, and are willing to follow all study procedures
• People aged between 18 and 75 years (inclusive)
• People who have been diagnosed (through tissue or cell testing) with a relapsed or treatment-resistant type of B-cell non-Hodgkin lymphoma, including specific subtypes such as diffuse large B-cell lymphoma, high-grade B-cell lymphoma, Grade 3B follicular lymphoma, transformed follicular or marginal zone lymphoma, primary mediastinal large B-cell lymphoma, Burkitt lymphoma, or mantle cell lymphoma
• People who have previously received standard treatments, including an anti-CD20 drug (unless the cancer does not have the CD20 marker) and an anthracycline chemotherapy drug
• People who either could not tolerate their most recent treatment, or whose doctor has assessed that new treatment is needed after the most recent treatment
• People whose cancer meets at least one measurable size requirement — either a lymph node tumour measuring more than 1.5 cm or an outside-lymph-node tumour measuring more than 1.0 cm on CT scan, or a PET scan score of 4 or 5
• People whose estimated survival is more than 12 weeks
• People with a general physical fitness score of 0 or 1 on the ECOG scale (meaning fully active or able to carry out light activities)
• People whose blood test results meet certain minimum thresholds for kidney function, liver function, blood clotting, blood oxygen levels, and heart pumping strength — without having received certain blood-boosting medications or transfusions in the 7 days before testing (confirm specific values with trial site)
• Women of childbearing potential who test negative for pregnancy at screening, and who agree to use highly effective contraception for 1 year after receiving the study treatment, and who agree not to donate eggs during the study or within 1 year after receiving the treatment
• Men who are sexually active with women who could become pregnant, who agree to use highly effective contraception for 1 year after receiving the study treatment, and who agree not to donate sperm during the study or within 1 year after receiving the treatment

Who may not be able to join:

• Women who are pregnant or breastfeeding
• People who have a history of neurological or brain conditions, such as epilepsy, stroke, dementia, Parkinson's disease, paralysis, memory impairment, mental illness, spinal cord compression, or any condition affecting the brain or central nervous system, or suspected cancer spread to the brain or nervous system
• People with HIV, syphilis, active hepatitis B, or active hepatitis C infection
• People who currently have any uncontrolled active infection, including active tuberculosis, based on the doctor's assessment
• People with a known or suspected long-standing active Epstein-Barr virus (EBV) infection, or a known history of a serious immune condition called haemophagocytic lymphohistiocytosis (HLH)
• People who have had an autologous (using their own cells) stem cell transplant or cell therapy within the 3 months before joining the study, or who have previously had an allogeneic (donor) stem cell transplant or donor cell therapy at any time
• People who have previously received treatment that specifically targeted the CD19 protein — unless testing shows the CD19 or CD20 marker is still present on the cancer
• People who have previously received a specific type of gene or viral therapy using a particular viral protein called VSVG as an envelope (confirm details with trial site)
• People who have received anti-cancer treatment within 14 days before the study infusion, or within 5 half-lives of the previous treatment (whichever is shorter), including chemotherapy, targeted therapy, radiotherapy, or experimental treatments
• People who have taken systemic steroid medications at a dose equivalent to more than 15 mg per day of prednisone within 7 days before joining the study (topical or low-dose replacement steroids may be acceptable — confirm with trial site)
• People who have received any vaccine within 4 weeks before joining the study, or who expect to receive a live, inactivated, or RNA vaccine during the trial or within 12 months after receiving the study treatment
• People with a known allergy to the study drug (CT1182) or any of its ingredients, an allergy or intolerance to a drug called tocilizumab, or a history of severe allergic reactions such as anaphylactic shock
• People with serious heart conditions, including severe heart failure (NYHA Class III or IV), a heart attack, unstable chest pain, or heart bypass or stent surgery within the past 6 months, clinically significant uncontrolled irregular heart rhythms, or other heart conditions that the doctor believes would make participation unsafe
• People with serious lung disease that the doctor believes would make participation unsafe
• People who have had another cancer requiring treatment within the past 3 years, with some exceptions for certain low-risk, successfully treated cancers (such as certain skin cancers, early-stage prostate cancer, breast or cervical cancer in situ, non-invasive bladder cancer, or thyroid cancer)
• People with an active autoimmune disease that requires ongoing treatment with immune-suppressing medications
• People who have had major surgery within 2 weeks before joining the study, or who are expected to need major surgery during the study or within 4 weeks after receiving the study treatment (minor procedures under local anaesthetic, such as cataract surgery, may be acceptable)
• People who the investigator assesses as unable or unwilling to follow the study requirements, or who are otherwise considered unsuitable for the trial

Important: Always verify eligibility with the trial site directly before applying.